Cardiovascular Systems Stock News

Cardiovascular Systems Inc (NASDAQ: CSII ), along with OrbusNeich Medical Company Ltd , have received FDA PMA approval for OrbusNeich''s Scoreflex NC Scoring Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheter (Scoreflex NC). Scoreflex NC is a focused force PTCA scoring balloon with a dual-wire system that creates a … Full story available on Benzinga.com

OrbusNeich Medical Company and its distribution partner in the U.S

Cardiovascular Systems Inc (NASDAQ: CSII), along with OrbusNeich Medical Company Ltd, have received FDA PMA approval for OrbusNeich's Scoreflex NC Scoring Percutaneous Transluminal Coronary Angio

Cardiovascular Systems (CSII) has developed intravascular lithotripsy systems to treat calcific coronary and peripheral artery diseases.

ATI Physical Therapy (ATIP) +16%. Cardiovascular Systems (CSII) +14%. Acutus Medical (AFIB) -9%. GeoVax Labs (GOVX) -9%.

Cardiovascular Systems Inc (NASDAQ: CSII) has announced the development of intravascular lithotripsy (IVL) technology for coronary and peripheral artery diseases. Enrolling patients in an investigati

Cardiovascular System (CSII) said that the company has made significant progress in its efforts to commercialize the intravascular lithotripsy ((IVL)) systems as a treatment for

Cardiovascular Systems (CSII) continues to experience strong demand for physician training and certification in all international markets.

Cardiovascular Systems Inc (NASDAQ: CSII) is recalling all of its Wirion embolic protection system devices manufactured and distributed between January and November 2021. The Wirion system includes

Cardiovascular Systems Inc. (CSII) shares closed today at 1.0% above its 52 week low of $17.96, giving the company a market cap of $735M. The stock is currently down 3.4% year-to-date, down 60.7% over the past 12 months, and down 22.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 48.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -17.1% The company's stock price performance over the past 12 months lags the peer average by -747.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. to Webcast Fiscal 2022 Second-Quarter Earnings Conference Call Thursday, February 3

DVA, CSII, BYND, AVYA, and GFF have been added to the Zacks Rank #5 (Strong Sell) List on December 28, 2021.

Cardiovascular Systems, Inc. (NASDAQ:CSII) shares hit a new 52-week low on Monday . The stock traded as low as $18.50 and last traded at $19.00, with a volume of 516232 shares. The stock had previously closed at $18.78. Several research analysts recently issued reports on CSII shares. Oppenheimer cut their price target on shares of []

Analysts expect that Cardiovascular Systems, Inc. (NASDAQ:CSII) will post $62.71 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Cardiovascular Systems earnings, with the lowest sales estimate coming in at $61.30 million and the highest estimate coming in at $66.30 million. Cardiovascular Systems reported sales of $64.17 []

Perkins Capital Management Inc. trimmed its holdings in shares of Cardiovascular Systems, Inc. (NASDAQ:CSII) by 56.4% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 21,767 shares of the medical device companys stock after selling 28,175 shares during the quarter. Perkins Capital Management Inc.s holdings in Cardiovascular Systems were worth $715,000 at the []